(New York, USA) DelveInsight’s “Asthma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Asthma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Asthma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Asthma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Asthma market.
Request for a Free Sample Report @ Asthma Market Forecast
Some facts of the Asthma Market Report are:
- According to DelveInsight, Asthma market size is expected to grow at a decent CAGR by 2032.
- Asthma market size was valued approximatley USD 18,460 million in 2022 and is anticiapted to grow with a siginificant CAGR during the study period (2019-2032)
- Leading Asthma companies working in the market are Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others
- Key Asthma Therapies expected to launch in the market are CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
- In February 2023, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.
Asthma Overview
Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections.
A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.
Learn more about Asthma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/asthma-market
Asthma Market
The Asthma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Asthma market trends by analyzing the impact of current Asthma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Asthma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Asthma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Asthma market in 7MM is expected to witness a major change in the study period 2019-2032.
Asthma Epidemiology
The Asthma epidemiology section provides insights into the historical and current Asthma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Asthma market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Asthma Epidemiology @ https://www.delveinsight.com/sample-request/asthma-market
Asthma Drugs Uptake
This section focuses on the uptake rate of the potential Asthma drugs recently launched in the Asthma market or expected to be launched in 2019-2032. The analysis covers the Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Asthma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Asthma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Asthma Pipeline Development Activities
The Asthma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Asthma key players involved in developing targeted therapeutics.
- MM09-MG01: Inmunotek S.L.
- BGF MDI: AstraZeneca
- GSK3511294: GlaxoSmithKline
- FP 025: Foresee Pharmaceuticals
- ADX-629: Aldeyra Therapeutics
- 610: Sunshine Guojian Pharmaceutical
- EDP1867: Evelo Biosciences, Inc.
- CM-326 : Keymed Biosciences
- 9MW1911: Mabwell (Shanghai) Bioscience Co., Ltd.
- Dapansutrile: Olatec Therapeutics
- LNR 125.38: Lanier Biotherapeutics
Request for a sample report to understand more about the Asthma pipeline development activities @ https://www.delveinsight.com/sample-request/asthma-market
Asthma Therapeutics Assessment
Major key companies are working proactively in the Asthma Therapeutics market to develop novel therapies which will drive the Asthma treatment markets in the upcoming years are are Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others
Learn more about the emerging Asthma therapies & key companies @ https://www.delveinsight.com/sample-request/asthma-market
Asthma Report Key Insights
1. Asthma Patient Population
2. Asthma Market Size and Trends
3. Key Cross Competition in the Asthma Market
4. Asthma Market Dynamics (Key Drivers and Barriers)
5. Asthma Market Opportunities
6. Asthma Therapeutic Approaches
7. Asthma Pipeline Analysis
8. Asthma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Asthma Market
Table of Content
1. Key Insights
2. Executive Summary
3. Asthma Competitive Intelligence Analysis
4. Asthma Market Overview at a Glance
5. Asthma Disease Background and Overview
6. Asthma Patient Journey
7. Asthma Epidemiology and Patient Population
8. Asthma Treatment Algorithm, Current Treatment, and Medical Practices
9. Asthma Unmet Needs
10. Key Endpoints of Asthma Treatment
11. Asthma Marketed Products
12. Asthma Emerging Therapies
13. Asthma Seven Major Market Analysis
14. Attribute Analysis
15. Asthma Market Outlook (7 major markets)
16. Asthma Access and Reimbursement Overview
17. KOL Views on the Asthma Market
18. Asthma Market Drivers
19. Asthma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage